Cargando…
Anti-integrin αvβ6 autoantibodies in patients with primary sclerosing cholangitis
BACKGROUND: Patients with primary sclerosing cholangitis (PSC) possess autoantibodies against biliary epithelial cells. However, the target molecules remain unknown. METHODS: The sera of patients with PSC and controls were subjected to enzyme-linked immunosorbent assays to detect autoantibodies usin...
Autores principales: | Yoshida, Hiroyuki, Shiokawa, Masahiro, Kuwada, Takeshi, Muramoto, Yuya, Ota, Sakiko, Nishikawa, Yoshihiro, Maeda, Hirona, Kakiuchi, Nobuyuki, Okamoto, Kanako, Yamazaki, Hajime, Yokode, Masataka, Nakamura, Takeharu, Matsumoto, Shimpei, Hirano, Tomonori, Okada, Hirokazu, Marui, Saiko, Sogabe, Yuko, Matsumori, Tomoaki, Mima, Atsushi, Uza, Norimitsu, Eso, Yuji, Takai, Atsushi, Takahashi, Ken, Ueda, Yoshihide, Kodama, Yuzo, Chiba, Tsutomu, Seno, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366314/ https://www.ncbi.nlm.nih.gov/pubmed/37310456 http://dx.doi.org/10.1007/s00535-023-02006-6 |
Ejemplares similares
-
Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021) -
Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021) -
Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022) -
Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury
por: Lleo, Ana, et al.
Publicado: (2022) -
Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)